PBYI
Puma Biotechnology, Inc.NASDAQHealthcareAs of 2026-04-06
Valuation
View DetailsP/E (TTM)
11.30
PEG
4.30
P/B
2.66
P/S
1.53
EV/EBITDA
5.92
DCF Value
$17.85
FCF Yield
11.9%
Div Yield
0.0%
Margins & Returns
Gross Margin
74.5%
Operating Margin
16.3%
Net Margin
13.6%
ROE
27.8%
ROA
14.4%
ROIC
20.4%
Financials
View All| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q4 2025 | $75.5M | $13.4M | $0.26 |
| FY 2025 | $228.4M | $31.1M | $0.61 |
| Q3 2025 | $54.5M | $8.8M | $0.17 |
| Q2 2025 | $52.4M | $5.9M | $0.12 |
Trading Activity
Insider Trades
View AllCompany Info
Sector
Healthcare
Industry
—
Country
US
Exchange
NASDAQ
Beta
1.18
Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company's drug candidates include PB272 neratinib (oral) for the patients with early stage HER2-overexpressed/amplified breast cancer; PB272 (neratinib, oral) for the use of neratinib in combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer; PB272 (neratinib, oral) for HER2 mutation-positive solid tumors. It has a license agreement with Pfizer, Inc.; and sub-license agreement with Specialised Therapeutics Asia Pte Ltd., CANbridge BIOMED Limited, Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. The company was founded in 2010 and is headquartered in Los Angeles, California.